Valneva SE (VALN) Cash from Financing Activities (2021 - 2024)
Valneva SE's (VALN) quarterly Cash from Financing Activities came in at -$4.9 million in Q4 2024, down 112.34% year-on-year from $39.7 million in Q1 2024, and down 100.03% quarter-over-quarter from $18.3 billion in Q3 2024.
Valneva SE (VALN) Cash from Financing Activities (2021 - 2024) Analysis & Trends
Valneva SE has disclosed Cash from Financing Activities across 4 years of filings, most recently posting -$4.9 million for Q4 2024.
- Cash from Financing Activities for Q4 2024 came in at -$4.9 million, down 112.34% year-over-year; the trailing twelve-month figure through Dec 2024 was $387.6 million (up 495.47% YoY), and the FY2025 annual result was -$722871.0, down 102.2% from the prior year.
- Cash from Financing Activities came in at -$4.9 million for Q4 2024 at Valneva SE, down from $18.3 billion in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $18.3 billion in Q3 2024 to a low of -$17.9 billion in Q2 2024.
- The 4-year median for Cash from Financing Activities is $8.9 million (2022), against an average of $53.6 million.
- Peak annual rise in Cash from Financing Activities reached 61612.28% in 2023, while the deepest fall reached 9392.38% in 2023.
- Valneva SE's Cash from Financing Activities stood at $91.4 million in 2021, then increased by 4.39% to $95.4 million in 2022, then sank by 58.32% to $39.7 million in 2023, then sank by 112.34% to -$4.9 million in 2024.
- The last three Cash from Financing Activities figures came in at -$4.9 million (Q4 2024), $18.3 billion (Q3 2024), and -$17.9 billion (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | 18.26 Bn |
| Sep 30, 2024 | 18.26 Bn |
| Jun 30, 2024 | -17.86 Bn |
| Jun 30, 2024 | -17.86 Bn |
| Mar 31, 2024 | -8.10 Mn |
| Mar 31, 2024 | -8.10 Mn |
| Dec 31, 2023 | 39.75 Mn |
| Dec 31, 2023 | 39.75 Mn |
| Sep 30, 2023 | 10.34 Bn |
| Sep 30, 2023 | 10.34 Bn |
| Jun 30, 2023 | -10.31 Bn |
| Jun 30, 2023 | -10.31 Bn |
| Mar 31, 2023 | -4.10 Mn |
| Mar 31, 2023 | -4.10 Mn |
| Dec 31, 2022 | 95.38 Mn |
| Dec 31, 2022 | 95.38 Mn |
| Sep 30, 2022 | 16.76 Mn |
| Sep 30, 2022 | 16.76 Mn |